Vericel Co. (NASDAQ:VCEL – Get Free Report) Director Robert L. Md Zerbe sold 2,200 shares of Vericel stock in a transaction on Friday, January 12th. The shares were sold at an average price of $38.09, for a total value of $83,798.00. Following the completion of the transaction, the director now owns 30,895 shares of the company’s stock, valued at approximately $1,176,790.55. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Vericel Price Performance
Shares of VCEL stock traded up $0.96 on Tuesday, reaching $39.20. 1,040,776 shares of the stock were exchanged, compared to its average volume of 1,162,268. Vericel Co. has a one year low of $26.88 and a one year high of $39.90. The stock has a 50 day moving average price of $35.40 and a 200 day moving average price of $34.87. The stock has a market cap of $1.87 billion, a PE ratio of -166.26 and a beta of 1.64.
Vericel (NASDAQ:VCEL – Get Free Report) last announced its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.05. Vericel had a negative return on equity of 5.19% and a negative net margin of 5.54%. The business had revenue of $45.58 million during the quarter, compared to analysts’ expectations of $45.14 million. On average, research analysts expect that Vericel Co. will post -0.18 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Vericel
Institutional investors have recently made changes to their positions in the stock. Pinebridge Investments L.P. grew its stake in shares of Vericel by 718.0% during the second quarter. Pinebridge Investments L.P. now owns 818 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 718 shares during the period. Acadian Asset Management LLC acquired a new position in Vericel in the second quarter valued at about $39,000. Fifth Third Bancorp grew its stake in Vericel by 38.3% in the second quarter. Fifth Third Bancorp now owns 1,210 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 335 shares during the period. Tower Research Capital LLC TRC grew its stake in Vericel by 174.3% in the first quarter. Tower Research Capital LLC TRC now owns 1,668 shares of the biotechnology company’s stock valued at $49,000 after acquiring an additional 1,060 shares during the period. Finally, Geneos Wealth Management Inc. acquired a new position in Vericel in the second quarter valued at about $84,000.
Wall Street Analysts Forecast Growth
Several brokerages have issued reports on VCEL. SVB Leerink began coverage on Vericel in a research report on Monday, October 16th. They issued an “outperform” rating and a $42.00 price objective for the company. Truist Financial lifted their price objective on Vericel from $33.00 to $39.00 and gave the company a “hold” rating in a research report on Thursday, November 9th. Stephens reiterated an “overweight” rating and issued a $44.00 price objective on shares of Vericel in a research report on Thursday, September 21st. Leerink Partnrs restated an “outperform” rating on shares of Vericel in a research report on Monday, October 16th. Finally, StockNews.com assumed coverage on Vericel in a research report on Thursday, October 5th. They set a “hold” rating for the company. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $42.00.
Vericel Company Profile
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns.